Amundi Sells 14,882 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Amundi decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 15.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 80,481 shares of the specialty pharmaceutical company’s stock after selling 14,882 shares during the quarter. Amundi owned 0.13% of Jazz Pharmaceuticals worth $9,676,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $9,335,000. Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $464,000. Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after acquiring an additional 48,708 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,736 shares of company stock worth $4,022,825. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $137.96 on Friday. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The stock’s 50 day moving average price is $129.52 and its two-hundred day moving average price is $120.76. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Barclays reaffirmed an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.